Severe psoriasis and atopic dermatitis: what to know before travelling for biologics

Severe psoriasis and atopic dermatitis are chronic inflammatory diseases with a systemic autoimmune component, and their impact goes far beyond the skin: disabling itch, insomnia, joint pain and enormous psychological strain.

Conventional treatments have been surpassed by biologic therapies, monoclonal antibodies blocking key cytokines: TNF-alpha, interleukin-17 or interleukin-23 in psoriasis, and the IL-4/IL-13 pathway in atopic dermatitis. More than 80% of chronic patients achieve almost complete skin clearance (PASI 90 or 100). As an adjunct, many centres integrate narrowband UVB phototherapy in favourable climates.

If you plan to start a biologic abroad, three points must not be overlooked. First, mandatory pre-screening: ruling out latent tuberculosis, hepatitis B and C, and updating vaccinations. Second, the main risk is selective immunosuppression that may predispose to respiratory infections, so you need clear action instructions. Third, and most important: this is continuous therapy, not a one-week treatment, so drug supply and funding must be guaranteed once you are home.

Thailand, Turkey and Spain host reference dermatology services able to perform screening, start drug induction and plan long-term follow-up in the home country. The range is EUR 2,000 to 8,000, with ten to twenty-one day stays.

Medviajes organises information and questions for medical travel planning. Confirm credentials, availability, prices and follow-up directly with the healthcare provider; this guide does not mean Medviajes books or delivers those services.